Deep Dives, AI, Drug Development, Drug Discovery.
to cover potential licensing deals for CytoReason’s AI platform and disease models. Meanwhile Bristol Myers Squibb agreed to pay up to $1.2 billion to enter a drug discovery collaboration with Exscientia, a U.K.-based pharmatech company with an AI platform that has designed two drugs that are in